Skip to main content

Table 2 Incidence of clinically significant deficits in QOL for each cohort

From: Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales

Cohorts

 

QOL score on 0–10 scale N (%)

 
 

Missing

<=5

>5 to <8

8-10

Total

Advanced cancer

7

25 (21%)

30 (25%)

65 (54%)

120

Brain cancer

0

8 (31%)

11 (42%)

7 (27%)

26

Breast cancer

0

27 (9%)

94 (32%)

175 (59%)

296

Clinical trial lung cancer

0

236 (20%)

350 (30%)

569 (49%)

1155

Colon cancer pts-2 wks post surgery (Colectomy)

63

67 (17%)

118 (30%)

203 (52%)

388

Colon cancer pts-pre surgery (Colectomy)

48

58 (14%)

85 (21%)

260 (65%)

403

GI cancer

0

287 (12%)

682 (28%)

1440 (60%)

2409

GU cancer

0

14 (8%)

41 (23%)

125 (69%)

180

Gynecologic cancer

0

14 (12%)

35 (30%)

68 (58%)

117

Head and neck cancer

0

54 (21%)

78 (31%)

122 (48%)

254

Hematologic cancer

0

4 (13%)

13 (41%)

15 (47%)

32

Lymphatic cancer

0

2 (25%)

1 (13%)

5 (63%)

8

Multiple site cancer

0

0 (0%)

5 (36%)

9 (64%)

14

Musculoskeletal site cancer

0

6 (33%)

5 (28%)

7 (39%)

18

Neurologic cancer

0

25 (12%)

75 (35%)

114 (53%)

214

Other cancer

0

8 (15%)

8 (15%)

36 (69%)

52

Lung cancer- Mayo study

0

137 (26%)

143 (27%)

249 (47%)

529

Lung cancer- Mayo study 6 months post diagnosis

0

326 (23%)

426 (30%)

657 (47%)

1409

Skin cancer

0

0 (0%)

4 (57%)

3 (43%)

7

Unknown site cancer

0

10 (34%)

9 (31%)

10 (34%)

29

Healthy NCCTG volunteers

0

1 (2%)

12 (22%)

41 (76%)

54

Hospice caregivers

4

9 (17%)

23 (43%)

21 (40%)

53

Hospice

5

22 (42%)

23 (44%)

7 (13%)

52

Minnesota medical students

2

84 (15%)

202 (37%)

257 (47%)

543

Mayo physicians

5

58 (13%)

174 (38%)

228 (50%)

460

Mayo residents

0

83 (28%)

125 (42%)

87 (29%)

295

Advanced cancer –psychosocial study

0

10 (23%)

24 (55%)

10 (23%)

44

  1. NCCTG, North central chapter treatment group.